Ignacio Durán

Marqués de Valdecilla University Hospital

Also affiliated with Instituto de Investigación Marqués de Valdecilla

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial”.

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(21)00757-9

N/A

4.9DataRank · unranked

188 citations

Howard I Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N Lara, Evan Y Yu +90 more

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

ESMO Open(2024)10.1016/j.esmoop.2024.103972

N/A

0.515DataRank · unranked

30 citations

M.D. Galsky, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Y. Loriot +19 more

Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes

British Journal of Urology(2021)10.1111/bju.15324

N/A

0.505DataRank · unranked

28 citations

Ali Raza Khaki, Leonidas Nikolaos Diamantopoulos, Lucía Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky +41 more

Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.06.001

N/A

0.505DataRank · unranked

28 citations

Rafee Talukder, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta +47 more

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.08.006

N/A

0.345DataRank · unranked

9 citations

Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta +49 more

Association of prior local therapy and outcomes with programmed‐death ligand‐1 inhibitors in advanced urothelial cancer

British Journal of Urology(2021)10.1111/bju.15603

N/A

0.283DataRank · unranked

5 citations

Rafee Talukder, Leonidas Nikolaos Diamantopoulos, Lucía Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky +42 more